Table 3.

Aim 1: combined effects of lower-leg injury and male, sex, age > 55 y, BMI > 30, comorbidity, oral contraceptives, factor V Leiden mutation, factor II mutation, and non-O blood group on the patterns of coagulation factor levels

Risk factorLower-leg injuryNumber of persons (N = 2306)Adjusted mean difference (95% CI)*
FVIII (%)FIX (%)FXI (%)VWF (%)Fibrinogen (mg/dL)D-dimer (ng/mL)
Male sex Absent Absent 437 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 581 −1.4 (−5.9 to 3.1) 0.5 (−2.3 to 3.2) −9.7 (−12.4 to −6.9) 3.7 (−1.9 to 9.3) −20.2 (−30.3 to −10.1) 0.8 (0.7-0.9) 
Absent Present 642 24.1 (19.8 -28.9) 13.2 (10.5 -15.8) 3.9 (1.3-6.6) 26.5 (21.2-31.9) 31.3 (21.6-41.0) 3.0 (2.7-3.4) 
Present Present 646 27.3 (22.7 -31.8) 14.9 (12.1 -17.7) −3.8 (−6.6 to −1.0) 35.6 (29.9 -41.2) 15.9 (5.626.1) 3.1 (2.7-3.4) 
Age > 55 y Absent Absent 703 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 315 11.4 (6.7-16.2) 6.9 (4.0-9.8) 2.4 (−0.5 to 5.2) 17.5 (11.7 -23.4) 15.7 (5.0-26.4) 1.5 (1.3-1.7) 
Absent Present 870 24.3 (20.7 -27.9) 11.4 (9.2 -13.6) 2.4 (0.2-4.6) 26.5 (22.0 -31.0) 20.5 (12.3-28.6) 3.2 (2.9-3.5) 
Present Present 418 38.4 (33.9 -43.0) 23.0 (20.2 -25.7) 10.8 (8.0 -13.6) 46.9 (41.3 -52.5) 66.1 (55.9-76.3) 5.4 (4.8-6.0) 
Obesity† Absent Absent 352 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 649 3.0 (−2.2 to 8.3) 12.9 (9.6-16.2) 5.3 (2.1-8.6) 1.6 (−4.8 to 8.1) 32.8 (21.0-44.7) 1.2 (1.0-1.3) 
Absent Present 586 25.3 (22.0 -28.5) 12.4 (10.3 14.4) 3.6 (1.6-5.6) 28.2 (24.1-32.2) 30.2 (22.8-37.7) 3.5 (3.3-3.8) 
Present Present 616 32.8 (27.0-38.5) 28.4 (24.8 -31.9) 13.1 (9.6 -16.7) 34.7 (27.6 -41.8) 71.0 (58.1-83.8) 3.5 (3.0-4.0) 
Comorbidity Absent Absent 917 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 83 −1.9 (−9.8 to 6.0) 5.9 (1.2-10.7) 1.8 (−3.1 to 6.6) 9.1 (−0.5 to 18.8) 12.4 (−5.3 to 30.1) 1.2 (1.0-1.4) 
Absent Present 1080 26.3 (23.2-29.4) 14.4 (12.5 -16.4) 5.4 (3.5-7.3) 29.2 (25.4 -33.1) 34.3 (27.3- 41.3) 3.5 (3.2-3.8) 
Present Present 138 27.0 (20.6 -33.4) 13.9 (10.0 -17.8) 2.0 (−1.9 to 5.9) 39.5 (−10.5 to −2.6) 42.2 (27.9- 56.5) 3.3 (2.8-3.9) 
Oral contraceptives use in women Absent Absent 343 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 85 14.4 (5.9 -23.0) 26.2 (20.5 -31.8) 13.6 (8.0 -19.2) 14.6 (3.8 -25.3) 28.8 (10.0-47.7) 1.4 (1.2-1.8) 
Absent Present 495 26.4 (21.6 -31.2) 15.0 (11.8 -18.2) 6.4 (3.2-9.6) 28.2 (22.2 -34.3) 35.8 (25.2-46.4) 3.1 (2.8-3.5) 
Present Present 110 30.9 (23.0 -38.9) 32.8 (27.5 -38.0) 6.5 (1.3-11.7) 39.3 (29.4 -49.3) 49.5 (32.0-67.0) 4.0 (3.3-4.8) 
Factor V Leiden mutation‡ Absent Absent 896 0.0 (Ref) 0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 34 5.7 (−6.3 to 17.8) 0.4 (−6.9 to 7.6) −4.3 (−11.6 to 3.0) −0.4 (−15.0 to 14.2) −5.4 (−32.2 to 21.4) 1.2 (0.9-1.6) 
Absent Present 1161 26.8 (23.6 -30.0) 14.3 (12.3 -16.2) 4.9 (3.06.9) 29.4 (25.5 -33.3) 35.9 (28.8-43.1) 3.5 (3.2-3.8) 
Present Present 50 30.9 (20.7 -41.1) 11.6 (5.5 -17.8) 3.9 (−2.3 to 10.1) 39.5 (26.8 -52.1) 20.8 (−2.0 to 43.5) 4.0 (3.1-5.1) 
Factor II 20210A mutation‡ Absent Absent 959 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 22 −3.5 (−18.3 to 11.3) −1.4 (−10.4 to 7.5) −4.0 (−13.0 to 5.0) −5.6 (−23.5 to 12.4) 0.6 (−32.3 to 33.5) 1.2 (0.8-1.7) 
Absent Present 1189 26.3 (23.2 -29.4) 13.7 (11.8-15.6) 4.7 (2.8-6.6) 29.1 (25.3 -32.9) 35.1 (28.2-42.0) 3.5 (3.2-3.8) 
Present Present 26 27.2 (12.9 -41.4) 10.8 (2.2 -19.3) −1.0 (−9.6 to 7.7) 28.9 (11.3 -46.5) 25.3 (−6.2 to 56.9) 4.1 (2.9-5.9) 
Non-O blood group‡ Absent Absent 403 0.0 (Ref) 0.0 (Ref) 0.0 (Ref 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 505 21.2 (16.8 -25.7) 6.4 (3.6-9.2) 6.6 (3.8-9.5) 36.6 (31.4 -41.8) −2.2 (−12.6 to 8.1) 1.1 (0.9-1.2) 
Absent Present 521 25.7 (21.2 -30.2) 14.5 (11.7 -17.3) 5.8 (3.0-8.7) 31.5 (26.2 -36.8) 40.4 (29.9-50.9) 3.6 (3.1-4.0) 
Present Present 682 47.8 (43.6 -52.1) 19.6 (16.9 -22.3) 11.0 (8.3 -13.7) 64.1 (59.1 -69.1) 28.4 (18.5-38.4) 3.6 (3.3-4.1) 
Risk factorLower-leg injuryNumber of persons (N = 2306)Adjusted mean difference (95% CI)*
FVIII (%)FIX (%)FXI (%)VWF (%)Fibrinogen (mg/dL)D-dimer (ng/mL)
Male sex Absent Absent 437 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 581 −1.4 (−5.9 to 3.1) 0.5 (−2.3 to 3.2) −9.7 (−12.4 to −6.9) 3.7 (−1.9 to 9.3) −20.2 (−30.3 to −10.1) 0.8 (0.7-0.9) 
Absent Present 642 24.1 (19.8 -28.9) 13.2 (10.5 -15.8) 3.9 (1.3-6.6) 26.5 (21.2-31.9) 31.3 (21.6-41.0) 3.0 (2.7-3.4) 
Present Present 646 27.3 (22.7 -31.8) 14.9 (12.1 -17.7) −3.8 (−6.6 to −1.0) 35.6 (29.9 -41.2) 15.9 (5.626.1) 3.1 (2.7-3.4) 
Age > 55 y Absent Absent 703 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 315 11.4 (6.7-16.2) 6.9 (4.0-9.8) 2.4 (−0.5 to 5.2) 17.5 (11.7 -23.4) 15.7 (5.0-26.4) 1.5 (1.3-1.7) 
Absent Present 870 24.3 (20.7 -27.9) 11.4 (9.2 -13.6) 2.4 (0.2-4.6) 26.5 (22.0 -31.0) 20.5 (12.3-28.6) 3.2 (2.9-3.5) 
Present Present 418 38.4 (33.9 -43.0) 23.0 (20.2 -25.7) 10.8 (8.0 -13.6) 46.9 (41.3 -52.5) 66.1 (55.9-76.3) 5.4 (4.8-6.0) 
Obesity† Absent Absent 352 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 649 3.0 (−2.2 to 8.3) 12.9 (9.6-16.2) 5.3 (2.1-8.6) 1.6 (−4.8 to 8.1) 32.8 (21.0-44.7) 1.2 (1.0-1.3) 
Absent Present 586 25.3 (22.0 -28.5) 12.4 (10.3 14.4) 3.6 (1.6-5.6) 28.2 (24.1-32.2) 30.2 (22.8-37.7) 3.5 (3.3-3.8) 
Present Present 616 32.8 (27.0-38.5) 28.4 (24.8 -31.9) 13.1 (9.6 -16.7) 34.7 (27.6 -41.8) 71.0 (58.1-83.8) 3.5 (3.0-4.0) 
Comorbidity Absent Absent 917 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 83 −1.9 (−9.8 to 6.0) 5.9 (1.2-10.7) 1.8 (−3.1 to 6.6) 9.1 (−0.5 to 18.8) 12.4 (−5.3 to 30.1) 1.2 (1.0-1.4) 
Absent Present 1080 26.3 (23.2-29.4) 14.4 (12.5 -16.4) 5.4 (3.5-7.3) 29.2 (25.4 -33.1) 34.3 (27.3- 41.3) 3.5 (3.2-3.8) 
Present Present 138 27.0 (20.6 -33.4) 13.9 (10.0 -17.8) 2.0 (−1.9 to 5.9) 39.5 (−10.5 to −2.6) 42.2 (27.9- 56.5) 3.3 (2.8-3.9) 
Oral contraceptives use in women Absent Absent 343 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 85 14.4 (5.9 -23.0) 26.2 (20.5 -31.8) 13.6 (8.0 -19.2) 14.6 (3.8 -25.3) 28.8 (10.0-47.7) 1.4 (1.2-1.8) 
Absent Present 495 26.4 (21.6 -31.2) 15.0 (11.8 -18.2) 6.4 (3.2-9.6) 28.2 (22.2 -34.3) 35.8 (25.2-46.4) 3.1 (2.8-3.5) 
Present Present 110 30.9 (23.0 -38.9) 32.8 (27.5 -38.0) 6.5 (1.3-11.7) 39.3 (29.4 -49.3) 49.5 (32.0-67.0) 4.0 (3.3-4.8) 
Factor V Leiden mutation‡ Absent Absent 896 0.0 (Ref) 0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 34 5.7 (−6.3 to 17.8) 0.4 (−6.9 to 7.6) −4.3 (−11.6 to 3.0) −0.4 (−15.0 to 14.2) −5.4 (−32.2 to 21.4) 1.2 (0.9-1.6) 
Absent Present 1161 26.8 (23.6 -30.0) 14.3 (12.3 -16.2) 4.9 (3.06.9) 29.4 (25.5 -33.3) 35.9 (28.8-43.1) 3.5 (3.2-3.8) 
Present Present 50 30.9 (20.7 -41.1) 11.6 (5.5 -17.8) 3.9 (−2.3 to 10.1) 39.5 (26.8 -52.1) 20.8 (−2.0 to 43.5) 4.0 (3.1-5.1) 
Factor II 20210A mutation‡ Absent Absent 959 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 22 −3.5 (−18.3 to 11.3) −1.4 (−10.4 to 7.5) −4.0 (−13.0 to 5.0) −5.6 (−23.5 to 12.4) 0.6 (−32.3 to 33.5) 1.2 (0.8-1.7) 
Absent Present 1189 26.3 (23.2 -29.4) 13.7 (11.8-15.6) 4.7 (2.8-6.6) 29.1 (25.3 -32.9) 35.1 (28.2-42.0) 3.5 (3.2-3.8) 
Present Present 26 27.2 (12.9 -41.4) 10.8 (2.2 -19.3) −1.0 (−9.6 to 7.7) 28.9 (11.3 -46.5) 25.3 (−6.2 to 56.9) 4.1 (2.9-5.9) 
Non-O blood group‡ Absent Absent 403 0.0 (Ref) 0.0 (Ref) 0.0 (Ref 0.0 (Ref) 0.0 (Ref) 1.0 (Ref) 
Present Absent 505 21.2 (16.8 -25.7) 6.4 (3.6-9.2) 6.6 (3.8-9.5) 36.6 (31.4 -41.8) −2.2 (−12.6 to 8.1) 1.1 (0.9-1.2) 
Absent Present 521 25.7 (21.2 -30.2) 14.5 (11.7 -17.3) 5.8 (3.0-8.7) 31.5 (26.2 -36.8) 40.4 (29.9-50.9) 3.6 (3.1-4.0) 
Present Present 682 47.8 (43.6 -52.1) 19.6 (16.9 -22.3) 11.0 (8.3 -13.7) 64.1 (59.1 -69.1) 28.4 (18.5-38.4) 3.6 (3.3-4.1) 
*

Adjusted for sex, age, BMI, comorbidity, presence of malignancy, and use of oral contraceptives.

†

Obesity defined as BMI > 30.

‡

Heterozygote and homozygote variants of factor V Leiden mutation, factor II mutation, and non-O blood group were combined.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal